At IDT Australia, we manufacture active pharmaceutical ingredients (APIs) and finished dose pharmaceuticals in a fully cGMP-compliant environment. Our commitment to quality underpins every stage of development and manufacture.

Compliance & Licences

IDT Australia operates in a fully cGMP-compliant environment and is subject to rigorous regulatory oversight. Our facility has been audited and accredited by:

  • Australian Therapeutic Goods Administration (TGA)
  • U.S. Food and Drug Administration (FDA)
  • Japanese Ministry of Health, Labour and Welfare (MHLW)
  • Australian Pesticides and Veterinary Medicines Authority (APVMA)
  • Through the Mutual Recognition Agreement (MRA), our GMP status is also recognised across Europe and Canada.

In addition, we hold Schedule 8 (S8) and Schedule 9 (S9) licences through the Office of Drug Control (ODC), enabling

  • Extraction and manufacture of medicinal cannabis products
  • Production of psychedelic materials for clinical trials